TD Cowen Maintains Buy on Legend Biotech, Lowers Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Yaron Werber maintains a Buy rating on Legend Biotech (NASDAQ:LEGN) but lowers the price target from $71 to $67.
July 15, 2024 | 4:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TD Cowen analyst Yaron Werber maintains a Buy rating on Legend Biotech but lowers the price target from $71 to $67.
The maintained Buy rating suggests continued confidence in the stock, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100